Orbimed Advisors LLC Acquires Shares of 635,000 Savara Inc. $SVRA

Orbimed Advisors LLC bought a new stake in Savara Inc. (NASDAQ:SVRA) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 635,000 shares of the company’s stock, valued at approximately $3,467,000.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Prudential Financial Inc. purchased a new position in Savara in the 2nd quarter valued at about $30,000. BNP Paribas Financial Markets increased its stake in Savara by 52.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after buying an additional 4,626 shares in the last quarter. Brevan Howard Capital Management LP purchased a new stake in Savara during the 2nd quarter worth approximately $33,000. Russell Investments Group Ltd. raised its holdings in shares of Savara by 930.5% during the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after acquiring an additional 9,463 shares during the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new position in shares of Savara during the third quarter valued at approximately $44,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Stock Performance

SVRA opened at $5.51 on Monday. Savara Inc. has a twelve month low of $2.43 and a twelve month high of $7.01. The firm has a market capitalization of $1.13 billion, a PE ratio of -9.84 and a beta of 0.24. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. The firm’s 50-day moving average price is $5.53 and its 200 day moving average price is $5.52.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). As a group, sell-side analysts expect that Savara Inc. will post -0.57 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on SVRA. Oppenheimer initiated coverage on Savara in a research report on Friday, April 24th. They issued an “outperform” rating and a $11.00 target price on the stock. Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Savara currently has an average rating of “Moderate Buy” and an average target price of $10.14.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.